Clinical Trial Update: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

View source ↗

Summary

A completed single-arm study in China evaluated the XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioplasty
• Cardiovascular Disease
• Coronary Artery Disease
• Coronary Heart Disease
• Coronary Restenosis
• Myocardial Infarction
• Stent Thrombosis
• Vascular Disease

Drugs mentioned

• XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) (everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Angioplasty, Cardiovascular Disease | Status: COMPLETED | Results posted: 2019-04-01